Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial

Christopher Adlbrecht, Jordi Rello(Centre Hospitalier Universitaire de Montpellier), Nina Wressnigg(Valneva (Austria)), Zsolt Molnár(Semmelweis University), Niranjan Kanesa-thasan(GlaxoSmithKline (United States)), Jacques Créteur, Andreas Meier‐Hellmann(Helios Kliniken), Mária Héjja(Országos Korányi Tbc és Pulmonológiai Intézet), Pieter Depuydt(Ghent University Hospital), Bernhard Schaaf(Klinikum Dortmund), Susanne Eder-Lingelbach(Valneva (Austria)), Thomas Staudinger(Northwestern University), Margot Vander Laenen(Ziekenhuis Oost-Limburg), Anton Klingler, Vladimír Šrámek, István Várkonyi(University of Debrecen), José A. Lorente(Universidad de Granada), Herbert Spapen(Universitair Ziekenhuis Brussel), Raphael Wurm(Medical University of Vienna), Katrin Dubischar(Valneva (Austria)), Hauke Schneider(University Hospital Augsburg), Philipp Eller(Federation of American Societies for Experimental Biology), Christian Zauner(Medical University of Vienna)
Critical Care
March 4, 2020
Cited by 83


Related Papers